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Abstract
Objective:To evaluate measures of sleep (exploratory endpoints) in two pivotal studies of amultilayer bead extended-release
methylphenidate (MPH-MLR) treatment of attention-deficit/hyperactivity disorder in children.
Methods: Study 1 evaluated the time course of response to MPH-MLR (n = 26) patients in an analog classroom setting
through four phases: screening (£28 days), open label (OL) dose optimization (4 weeks), double-blind (DB) crossover (2
weeks; placebo vs. optimized dose), and follow-up call. Study 2was a forced-dose parallel evaluation ofMPH-MLR (n = 230)
in four phases: screening (£28 days), DB (1week; placebo orMPH-MLR 10, 15, 20, or 40mg/day), OL dose optimization (11
weeks), and follow-up call. Sleep was evaluated by parents using the Children’s or Adolescent Sleep Habits Questionnaire
(CSHQ or ASHQ) during the DB and OL phases. DB analysis: Study 1 (crossover), analysis of variance; Study 2, analysis of
covariance. OL analysis: paired t-test.
Results: DB: treatments were significantly different in Study 1 only for CSHQ Sleep Onset Delay (MPH-MLR, 1.90 vs.
placebo, 1.34; p = 0.0046, placebowas better), and Study 2 for CSHQParasomnias (treatment, p = 0.0295), but noMPH-MLR
treatment was different from placebo (pairwiseMPH-MLR treatment to placebo, all p ‡ 0.170). OL: CSHQ total and Bedtime
Resistance, Sleep Duration, Sleep Anxiety, Night Wakings, Parasomnias, and Sleep-disordered Breathing subscales
decreased (improved, Study 1) significant only for CSHQ Night Wakings ( p < 0.05); in Study 2 CSHQ total and Bedtime
Resistance, Sleep Duration, Night Wakings, Parasomnias, and Daytime Sleepiness, and ASHQ total, Bedtime, Sleep
Behavior, and Morning Waking all significantly improved ( p < 0.05).
Conclusions: In both studies, there was minimal negative impact of MPH-MLR on sleep during the brief DB phase and none
during the longer duration OL phase. Some measures of sleep improved with optimized MPH-MLR dose.
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Introduction
Children, adolescents, and adults with attention-deficit/hyperactivity disorder (ADHD) frequently present with a variety
of sleep-related difficulties before receiving ADHD medications
(Stein et al. 2012; Kidwell et al. 2015). The impact of ADHD med-
ications on sleep has been debated, with some studies showing del-
eterious effects on sleep, some studies showing minimal effects on
sleep, and other studies showing improvement in sleep parameters
after treatment with ADHD medications (Kidwell et al. 2015). The
potential for different ADHD medications with varying pharmaco-
kinetic profiles to have different impacts on sleep parameters also has
been a topic of research and clinical discussion.
Forty to fifty percent of parents report sleep-related problems in
their children with ADHD, particularly resistance to bedtime and/or
delayed sleep onset (Owens 2009). When studies comparing chil-
dren with ADHD with controls were evaluated, it was noted that
children with ADHD had higher scores for bedtime resistance,
sleep latency, morning awakening challenges, nighttime awaken-
ings, sleep-disordered breathing, and daytime sleepiness (Cortese
et al. 2009). Complicating the matter further is that many children
with ADHD have comorbid psychiatric conditions, such as anxiety
or depression, which also may affect sleep (Mayes et al. 2009;
Accardo et al. 2012).
A population-based ADHD study conducted by the Australian
government found that children with ADHD with insomnia had
significantly worse psychosocial outcomes, missed more days of
school, and their parents also missed more days of work (Sung et al.
2008). Primary sleep disorders coexisting with ADHD such as
sleep-related movement disorders (Walters et al. 2008), circadian
sleep disorders (Chiang et al. 2010; Gruber et al. 2012), and sleep-
related breathing disorders (Cortese et al. 2006) often further com-
plicate the sleep challenges in children and adolescents with ADHD.
Clinically, children and adolescents with insufficient or poor
quality sleep often demonstrate behaviors of inattention and hyper-
activity that may be misinterpreted as symptoms of ADHD (Owens
2009; Cassoff et al. 2012; Hvolby 2015; National Sleep Foundation
2015). In contrast to adults who generally exhibit fatigue and
sleepiness in the face of insufficient or disrupted sleep, children’s
behavioral response to subjective sleepiness may manifest as
increased activity levels as well as behavioral and mood dysregu-
lation (Owens 2009).
Further complicating these relationships is the potential impact
of ADHD stimulant medications on sleep. A recent meta-analysis
of articles in which stimulants were used for ADHD found that
worsening sleep latency was seen in some patients receiving
stimulants and that this finding was more common in patients
receiving more frequent stimulant dosing (Kidwell et al. 2015).
Extended-release stimulant formulations given once daily had less
impact on sleep latency than thrice-daily immediate-release dosing.
These researchers also found that patients receiving stimulants had
poorer sleep efficiency (i.e., time asleep/time in bed) than patients
not receiving stimulants. This effect appeared to be attenuated with
prolonged dosing (Kidwell et al. 2015).
Several clinical trials of long-acting stimulant medication have
now examined sleep outcomes as a secondary outcome. Most of
these studies have used subjective measures such as parent report.
A study of the impact of OROS methylphenidate ( Janssen Phar-
maceuticals, Inc., Titusville, NJ) on sleep using the Children’s
Sleep Habits Questionnaire (CSHQ) demonstrated improvement in
parasomnias and no overall effect on sleep onset latency, although
there was worsening in those children who had sleep complaints
(Kim et al. 2010). This study also used the objective measure
polysomnography and found an increase in stage 2 sleep and
improvement in the number of awakenings.
A study of the impact of lisdexamfetamine on sleep in children
using the objective measures polysomnography and actigraphy as
well as subjective parent report did not find any statistically sig-
nificant increase in the primary endpoint of latency to persistent
sleep on any of the three measures (Giblin and Strobel 2011).
Subjective sleep measure results indicated the possibility that
responses are influenced by sleep hygiene counseling before and
throughout the study. These studies demonstrate that assessment of
sleep as an outcome in its own right, as opposed to looking at
sleep as an adverse event may provide us with a better under-
standing of the specifics of both the benefit and risk of stimulant
treatment to children, facilitate the identification of children at risk,
and identify the specific objective and subjective sleep parameters
that may be impacted.
Aptensio XR (Rhodes Pharmaceuticals L.P., Coventry, RI) is a
multilayer bead extended-release methylphenidate (MPH-MLR)
capsule formulation, in which each bead has 40% of the MPH
located in the immediate-release outer layer and 60% of the
methylphenidate located in a pH-dependent extended-release layer
(Aptensio XR prescribing information 2015). Administration of
MPH-MLR results in a biphasic pattern of methylphenidate plasma
concentration with an initial peak at 2 hours postdose, gradually
declining concentration over the next 4–6 hours, and a secondary
peak *8 hours postdose with gradually declining concentration
thereafter (Fig. 1) (Adjei et al. 2014; Aptensio XR prescribing
information 2015).
In an analog classroom study (Study 1), significant improve-
ments in ADHD symptoms were observed 1 hour after admin-
istration of MPH-MLR and sustained for ‡12 hours, with no
diminution of effect (Wigal et al. 2014). The pivotal studies sup-
porting marketing approval for MPH-MLR demonstrated that it is
efficacious for ADHD in children and adolescents, as evaluated in
both analog classroom and outpatient environments (Wigal et al.
2014, 2015).
Assessment of sleep was included in the design of the MPH-
MLR pivotal studies as an exploratory endpoint to investigate the
impact of MPH-MLR treatment on parent- and self-reported sleep
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FIG. 1. Mean plasma MPH concentration versus time following
a single dose of MPH-MLR capsule or sprinkles. MPH, methyl-
phenidate; MPH-MLR, multilayer bead extended-release methyl-
phenidate.
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difficulties. We report the results of analyses of these endpoints to
further the understanding of the impact of a long-acting methyl-
phenidate preparation on parent-reported sleep.
Methods
Studies
Two randomized, double-blind (DB), placebo-controlled, phase
3 studies were included in the MPH-MLR clinical development pro-
gram (Wigal et al. 2014, 2015). Study 1 (ClinicalTrials.gov Identifier:
NCT01269463) evaluated the time course of response to MPH-MLR
in an analog classroom setting (Wigal and Wigal 2006) and included
four phases: screening (£28 days), open label (OL) dose optimization
(4 weeks), DB crossover (2 weeks), and follow-up call (Wigal et al.
2014). Children (male or female) aged 6–12 years at the time of
consent with any of the three subtypes of ADHD as defined by the
Diagnostic and StatisticalManual ofMentalDisorders, fourth edition,
text revision (DSM-IV-TR) (American Psychiatric Association 2000)
were eligible for inclusion in the study. Exclusion criteria included
severe concurrent psychiatric or medical illness and functioning at an
estimated intellectual level <80 on the Wechsler Abbreviated Scale
of Intelligence.
During the OL dose-optimization phase, dosing was initiated
withMPH-MLR 15mg and titrated weekly over the next 2–4 weeks
to an optimized dose of 15, 20, 30, or 40mg. Patients were then
randomized in a 1:1 ratio to one of two treatment sequence groups
(optimized dose–placebo or placebo–optimized dose). The opti-
mized dose or placebo was administered for 1 week, and the patient
participated in an analog classroom study day and crossed over to
the second treatment and participated in a second analog class-
room day. The primary efficacy endpoint was the mean of the DB
on-treatment postdose Swanson, Kotkin, Agler, M-Flynn, and
Pelham (SKAMP)-total scores over time points 1.0, 2.0, 3.0, 4.5,
6.0, 7.5, 9.0, 10.5, and 12.0 hours during the classroom day.
Study 2 (ClinicalTrials.gov Identifier: NCT01239030) was a
fixed-dose evaluation of MPH-MLR safety/efficacy with the
assigned dose given from day 1 with no titration. The four study
phases included screening (£28 days), DB (1 week), OL dose
optimization (11 weeks), and follow-up call (Wigal et al. 2015).
This study included children and adolescents (male and female)
aged 6–18 years at the time of consent with an ADHD diagnosis as
defined in the DSM-IV-TR. Exclusion criteria were similar to
Study 1.
During the DB phase, patients were randomized (1:1:1:1:1) to
receive MPH-MLR 10, 15, 20, or 40mg, or placebo. During the
11-week OL dose-optimization phase, treatment was initiated with
the once-daily MPH-MLR 10mg dose and titrated (up or down) at
weekly intervals until the optimal dose was achieved. MPH-MLR
capsules of 10, 15, 20, 30, 40, 50, and 60mg were available in the
OL dose-optimization phase. The primary efficacy endpoint mea-
sure was the change from baseline to the end of the DB phase in the
clinician-rated ADHD Rating Scale-IV total score.
All participants and/or legal guardians provided written
informed consent in both studies before receiving pre-enrollment,
psychiatric and medical evaluations. Both studies were conducted
in compliance with Good Clinical Practice guidelines of the
International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use, the
United States Code of Federal Regulations that relate to clinical
trial conduct, and the principles of the Declaration of Helsinki.
Further study details for Studies 1 and 2 have been published
elsewhere (Wigal et al. 2014, 2015).
In both studies, sleep was evaluated in children aged 6–12 years
using the parent-reported CSHQ as well as the child-reported Sleep
Self-Report (SSR). For adolescents aged 13–18 years, modified
versions of the Adolescent Sleep Habits Questionnaire (ASHQ;
parent report and self-report) were used. In Study 1, sleep assess-
ments were collected at baseline, the end of OL dose-optimization
phase (beginning of the DB phase), and weekly during the DB
crossover phase. In Study 2, sleep assessments were collected at the
beginning and end of the DB phase and again at the end of the OL
dose-optimization phase.
Assessments
The CSHQ is a retrospective 48-item parent questionnaire used to
examine sleep behavior that has been validated in young children
(aged 4–10 years) (Owens et al. 2000b). It includes items relating to a
number of key sleep domains that encompass the major presenting
clinical sleep complaints in this age group. Parents are asked to recall
sleep behaviors occurring over a typical recent week and to rate the
behavior on a three-point scale scored 1–3, with a higher score in-
dicative of more problems.
Ratings for most items were as follows: ‘‘usually’’ if something
occurred 5–7 times in a week, ‘‘sometimes’’ if it occurred 2–4 times
in a week, or ‘‘rarely’’ if something occurred 0–1 time in a week.
Two items required the rating to be ‘‘not sleepy,’’ ‘‘very sleepy,’’ or
‘‘falls asleep.’’ Thirty-three items were grouped into eight sub-
scales: Bedtime Resistance, Sleep Onset Delay, Sleep Duration,
Sleep Anxiety, Night Wakings, Parasomnias, Sleep-Disordered
Breathing, and Daytime Sleepiness. Scale scores were the sum of
the scores for items in the scale. If an item from a scale was not
rated, the scale score was taken as missing.
The SSR is a 26-item questionnaire that has been used in pre-
vious studies (Owens et al. 2000a, 2000c) to measure sleep dis-
turbances reported by children themselves. Twenty-three items
were grouped into three subscales for this analysis: Bedtime, Sleep
Behavior, and Daytime Sleepiness. Scoring of items and scales
mirrored the parent-reported version.
The ASHQwas developed to parallel the parent- and self-reported
versions of the CSHQ and examines sleep behavior in adolescents
(aged 13–18 years); its structure is similar to the CSHQ. The ASHQ-
Parent version was administered by clinicians and directed to par-
ents. For each item there were four possible responses (never= 0· /
week; rarely = 1–2 · /week; sometimes = 3–5 · /week; usually =
6–7· /week). Items were grouped into the following six subscales:
Bedtime, Sleep Behavior, Waking During the Night, Morning
Waking, Sleep Habits, and Daytime Sleepiness. Item scores
ranged from 0 to 3, with higher scores more indicative of sleep
problems. In this study, the ASHQ was modified to include a
response of ‘‘don’t know.’’ Scoring was taken as the mean of the
nonmissing data times the number of items in the scale because of
‘‘don’t know’’ responses. The clinician administered a slightly
different version of the ASHQ to adolescents (ASHQ-Self).
ASHQ-Self scoring and groupings were similar to the ASHQ-
Parent report.
Analysis
In Study 1, the observed DB data were analyzed using an analysis
of variance appropriate for a crossover study with terms for subject,
treatment, period, and sequence. In Study 2, the change during the
DB phase was analyzed using an analysis of covariance appropriate
for a parallel study with terms for treatment and site and with each
patient’s baseline score as a covariate with a pairwise comparison of
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each MPH-MLR treatment to placebo using Dunnett’s test. In both
studies, the analysis of the OL dose-optimization phase in each study
was a paired t-test comparing the start of studywith the end of theOL
dose-optimization phase. All p-values were two sided.
Results
Patient demographics
Study 1 included 26 patients who completed screening and
received at least one dose of study drug and 20 patients who
completed SKAMP assessments for all study time points and
received the scheduled treatments (Wigal et al. 2014). At screening,
two patients were receiving psychotropic medication. The mean
(standard deviation [SD]) optimized dose of MPH-MLR was 25.7
(6.2) mg. Study 2 included 230 patients who completed screening
and received at least one dose of study drug, and 221 children and
adolescents who completed the ADHD Rating Scale-IV assess-
ments on days 0 and 7 (Wigal et al. 2015). At screening, 74 patients
were receiving psychotropic medication.
In Study 2, the mean (SD) optimized dose of MPH-MLR was
36.6 (12.8) mg or 0.93 (0.47) mg/kg. The relationship between
optimized dose and weight was not statistically significant (linear
regression, slope, p = 0.1049). In the DB phase, mean MPH-MLR
mg/kg doses were as follows: 10mg (0.27mg/kg), 15mg (0.41mg/
kg), 20mg (0.52mg/kg), and 40mg (0.89mg/kg). In each study, the
population was largely white (81% in Study 1, 69% in Study 2) and
themajority of patients weremale (54% in Study 1, 67% in Study 2)
(Wigal et al. 2014, 2015). At study entry, there was evidence of
sleep impairment (Table 1).
Study 1
During the 4-week OL dose-optimization phase, scores decreased
(improved) from baseline for CSHQ total score and Bedtime
Resistance, Sleep Duration, Sleep Anxiety, Night Wakings, Para-
somnias, and Sleep-Disordered Breathing subscale scores, although
the improvement was only significant for Night Wakings (Table 2).
Scores increased (worsened) for Sleep Onset Delay and Daytime
Sleepiness subscale scores, but neither was significant. Individual
Sleep Onset Delay subscale scores showed that 66.7% (16/24) of
patients had no change, 20.8% (5/24) worsened, and 12.5% (3/24)
improved. SSR total score and Bedtime and Daytime Sleepiness
subscale scores also improved, while Sleep Behavior subscale
score worsened, but none reached statistical significance.
During the 2-week DB crossover phase, CSHQ ratings for the
Sleep Onset Delay subscale were significantly higher (worse) for
optimizedMPH-MLR dose than placebo (1.9 vs. 1.34, respectively;
p = 0.0046; Table 3), while CSHQ total score and other subscales
were not significantly different between placebo and optimized
MPH-MLR dose. Individual patient scores for the Sleep Onset
Delay subscale showed that MPH-MLR and placebo scores were
not different for 60% (12/20) of patients and indicated more
problems (higher score) for 40% (8/20) of patients. SSR score for
the DB phase did not show any statistically significant difference
between placebo and optimized dose for the SSR total or any
subscale scores (Table 2).
Table 1. Initial Assessmentsa of Sleep
in the Multilayer Bead Extended-Release
Methylphenidate Phase 3 Studies
Study 1 (n= 26) Study 2
Mean (SD) CSHQ total score
Parent 49.1 (10.10) 46.9 (7.84), n = 130
Mean (SD) ASHQ total score
Parent NA 44.8 (13.96), n = 74
CSHQ scores >41 are indicative of a sleep disorder (Owens et al. 2000b).
aBeginning of the study.
ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ, Children’s
Sleep Habits Questionnaire; NA, not applicable (only children aged £12
years included in study); SD, standard deviation.
Table 3. Sleep Scores During the 2-Week
Double-Blind Crossover Phase (Study 1;
Evaluable Population; n= 20)
LS mean pa
MPH-MLR Placebo Treatment
CSHQ-Parent
Total 46.5 44.4 0.1466
Bedtime Resistance 9.1 8.8 0.5342
Sleep Onset Delay 1.9 1.3 0.0046
Sleep Duration 4.6 4.0 0.1282
Sleep Anxiety 5.4 5.4 0.8885
Night Wakings 3.7 3.5 0.3955
Parasomnias 8.2 8.1 0.4973
Sleep-Disordered
Breathing
3.2 3.2 0.6548
Daytime Sleepiness 13.4 12.9 0.3052
SSR
Total 39.9 41.2 0.2507
Bedtime 21.1 21.5 0.5642
Sleep Behavior 11.3 11.8 0.4142
Daytime Sleepiness 7.5 7.9 0.1992
aMixed-effects analysis of variance, fixed terms for treatment, period,
and sequence; random term for subject within sequence.
CSHQ,Children’s SleepHabitsQuestionnaire;LS, least-squares;MPH-MLR,
multilayer bead extended-release methylphenidate; SSR, Sleep Self-Report.
Table 2. Change in Sleep Scores During the 4-Week
Open-Label Dose-Optimization Phase (Study 1; n= 24)
Mean (SD) decrease pa
CSHQ-Parent
Total 2.1 (7.87) 0.2074
Bedtime Resistance 1.0 (2.51) 0.0538
Sleep Onset Delay -0.1 (0.68) 0.3769
Sleep Duration 0.2 (2.04) 0.6921
Sleep Anxiety 0.6 (1.69) 0.0830
Night Wakings 0.5 (0.93) 0.0243
Parasomnias 0.5 (1.38) 0.0674
Sleep-Disordered Breathing 0.1 (0.45) 0.1853
Daytime Sleepiness -0.3 (3.29) 0.7129
SSR
Total 1.2 (5.70) 0.3100
Bedtime 1.0 (3.39) 0.1617
Sleep Behavior -0.3 (2.15) 0.5748
Daytime Sleepiness 0.5 (2.30) 0.3397
ap-Values are from paired t-test for the change from study start to end of
the open-label phase.
CSQH, Children’s Sleep Habits Questionnaire; SD, standard deviation;
SSR, Sleep Self-Report.
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Safety data from Study 1 also were reviewed for sleep-related
adverse events. Insomnia was reported as an adverse event by
30.8% (8/26) of patients in the OL dose-optimization phase and
0.0% (0/21) and 4.5% (1/22) of patients receiving MPH-MLR
or placebo, respectively (DB crossover phase). Discontinuations
related to insomnia were few: None during the DB phase and
only one of four discontinuations during the OL dose-optimization
phase.
Study 2
During the initial 1-week DB fixed-dose phase, there was no
significant difference among treatments for CSHQ total or any
subscale except for Parasomnias (Table 4). For the Parasomnias
subscale score, p-values from Dunnett’s multiple comparison
follow-up comparison of each MPH-MLR treatment with placebo
were significant only for the 10mg dose ( p = 0.0170 [10mg],
p = 0.9071 [15mg], p = 0.9674 [20mg], p= 0.2338 [40mg]). There
was no difference in Sleep Onset Delay subscale score during the
DB phase, even with higher MPH-MLR doses. There were no
significant treatment differences for changes on the SSR or ASHQ-
Parent or ASHQ-Self during the DB phase.
During the 11-week OL dose-optimization phase, mean total and
all subscale scores decreased from baseline (fewer sleep-related
problems) for the CSHQ, SSR, and ASHQ-Parent, and most sub-
scale scores were significant (Table 5). At end of OL, CSHQ scores
were significantly lower for the following: total score and Bedtime
Resistance, Sleep Duration, Night Wakings, Parasomnias, and
Daytime Sleepiness subscale scores. ASHQ-Parent total score and
Bedtime, Sleep Behavior, and Morning Waking subscale scores
were also significantly lower at the end of OL dose optimization.
For the ASHQ-Self, all scales decreased significantly, except for
the Sleep Habits and Bedtime subscales, which decreased, but not
significantly. During the OL dose-optimization phase, CSHQ Sleep
Onset Delay subscale score did not change in 59.6% (81/136) of
patients, worsened in 16.2% (22/136) of patients, and improved in
24.3% (33/136) of patients.
During the 1-week, DB phase, insomnia was reported as an
adverse event by 9.8% (18/183) and 2.1% (1/47) of patients
receiving MPH-MLR or placebo, respectively. The rate of reported
insomnia did not appear to increase as dose increased: 10mg (5/49
[10.2%]), 15mg (2/44 [4.5%]), 20mg (6/45 [13.3%]), and 40mg
(5/45 [11.1%]). During the OL dose-optimization phase, 11.8%
(26/221) of patients reported insomnia as an adverse event. In the
Table 4. Change in Sleep Scores During the 1-Week Double-Blind Phase (Study 2; Evaluable Population; n = 221)
LS mean decrease
pa
MPH-MLR
10mg
MPH-MLR
15mg
MPH-MLR
20mg
MPH-MLR
40mg Placebo Treatment
CSHQ
Total (n= 124) -0.2 1.2 0.9 1.7 1.5 0.5184
Bedtime Resistance -0.2 0.1 -0.2 0.3 0.2 0.5214
Sleep Onset Delay 0.1 0 -0.1 -0.1 0 0.7900
Sleep Duration -0.2 0 -0.3 0 0 0.9476
Sleep Anxiety -0.2 0.2 0.1 0 0.1 0.4236
Night Wakings 0.1 0.1 0.1 0 0 0.9859
Parasomnias -0.2 0.5 0.6 0.1 0.7 0.0295
Sleep-Disordered Breathing -0.1 0.1 0 0 0.1 0.4216
Daytime Sleepiness 0.1 0.6 0.6 1.2 0.6 0.5483
SSR
Total (n= 135) -0.7 1.0 2.5 1.1 0.4 0.1604
Bedtime -0.3 0.5 1.1 0.3 0.7 0.4904
Sleep Behavior 0 0.2 0.1 0.3 0 0.9743
Daytime Sleepiness -0.1 0.4 0.7 0.4 0 0.2289
ASHQ-Parent
Total (n= 74) 0.9 4.5 3.9 4.9 0.9 0.4485
Bedtime 0 1.8 1.1 1.5 -0.7 0.2482
Sleep Behavior 0.4 0 1.1 1.2 0.6 0.8334
Waking During the Night 0.4 0.9 0.9 0.7 0.7 0.9528
Morning Waking -0.2 0.2 0.1 0 0.1 0.9978
Sleep Habits -0.5 0.1 0.1 0.5 -0.4 0.4594
Daytime Sleepiness 0.5 0.3 1.3 0.7 0.4 0.9418
ASHQ-Self
Total (n= 71) 2.9 10.4 4.5 5.8 3.2 0.3219
Bedtime 1.0 0.8 0.6 1.1 0.8 0.9966
Sleep Behavior 0.8 1.5 1.2 1.4 0.8 0.9677
Waking During the Night 0 1.5 0.4 0.6 0.9 0.4306
Morning Waking 0.8 2.0 0.3 0.9 1.1 0.7464
Sleep Habits -0.2 -0.6 0.6 -0.2 -0.4 0.1845
Daytime Sleepiness 0.8 1.6 2.1 1.8 0.2 0.1853
aAnalysis of covariance model has fixed terms for treatment and sites; covariate is baseline score. Sites with <10 patients combined.
ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ; Children’s Sleep Habits Questionnaire; LS, least-squares; MPH-MLR, multilayer bead
extended-release methylphenidate; SSR, Sleep Self-Report.
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DB phase, 11.1% (1/9) of patients discontinued owing to insomnia.
In the OL dose-optimization phase, 19.0% (4/21) of patients dis-
continued owing to insomnia.
Discussion
The results of these studies suggest that while MPH-MLR, an
extended-release methylphenidate, negatively impacted some
dimensions of sleep such as sleep onset latency, it also had bene-
ficial effects on other dimensions of sleep. Previous research has
focused predominantly on psychostimulant-associated ‘‘insomnia’’
as an adverse event loosely defined by the investigator, which is
often not further differentiated as difficulty with sleep onset or sleep
maintenance. These differences in insomnia definition may account
for the apparent discrepancy between no change or improvements
in CSHQ sleep parameters and rates of reported insomnia adverse
events during the longer study phases (dose-optimization phase in
Study 1 and OL phase in Study 2).
The finding in this study that stimulant administration was asso-
ciated with a delay in sleep onset compared with placebo is similar to
a number of other studies of children with ADHD. As noted in the
introduction, a meta-analysis of studies that reported sleep data in
patients treated with stimulants noted that patients themselves and/or
parents of children or adolescents with ADHD more frequently re-
port problems with prolonged sleep onset latency and decreased
sleep efficiency (Kidwell et al. 2015).
Another meta-analysis of studies that used actigraphy (wristwatch-
like device that captures and stores body movement data to
approximate sleep/wake patterns) to monitor sleep effects found a
significant impact of methylphenidate administration on total sleep
time (decreased) (De Crescenzo et al. 2014). Both sleep onset
latency and total sleep time were negatively impacted by methyl-
phenidate administration in another study of 21 children aged 6–12
years (Corkum et al. 2008). In another 8-week randomized cross-
over study, 37 children aged 10–17 years received extended-release
dexmethylphenidate and extended-release mixed amphetamine
salts (Santisteban et al. 2014). Both medications decreased sleep
duration as measured by actigraphy, and there was no significant
difference between the two medications. Higher doses were asso-
ciated with a later sleep onset and shorter sleep duration (Santis-
teban et al. 2014).
In contrast, our findings suggest that while improvement in sleep
parameters, as evidenced by a decrease in total and subscale sleep
survey scores, was generally not seen over the short duration of the
DB phase in each of these studies, there also was no evidence that
sleep deteriorated during this time. Furthermore, prolonged admin-
istration of MPH-MLR at an optimized dose in the OL phase of both
studies appeared to result in some improvement in sleep parameters.
As previously described, the possibility that administration of
stimulants, including methylphenidate, might have a null or even
beneficial effect on some aspects of sleep has been reported in the
literature (Kim et al. 2010; Giblin and Strobel 2011).
Similar to the results of these studies, in a study of once-daily
oral or transdermal methylphenidate, there was little evidence
suggesting a negative impact of treatment on sleep parameters,
particularly once an optimized dose was achieved (Faraone et al.
2009). A study of children in Thailand with ADHD aged 5–12 years
found no significant differences in sleep difficulties in children who
were receiving ADHD treatment with stimulants and those who
were not (Chiraphadhanakul et al. 2015). An observational sleep
study in children with ADHD reported little evidence that sup-
ported a substantial effect in objective or subjective measures of
sleep (O’Brien et al. 2003); even a third dose of methylphenidate
administered late in the day to children with ADHD did not appear
to have a negative impact on sleep (Kent et al. 1995).
Finally, polysomnography data from children treated with
OROS methylphenidate actually showed a significant decrease in
the number of awakenings (Kim et al. 2010), and subjective mea-
sures in another study indicated that nighttime awakenings were
improved in children with ADHD treated with thrice-daily meth-
ylphenidate (Sangal et al. 2006).
In general, subjective reports in these studies were consistent
with objective findings, when available. In addition, these subjec-
tive measures provided information on parent experience of sleep
in their children over time which is different from, but as important
as, the objective impact on sleep itself. It is frequently the care-
giver report that defines behaviors as a ‘‘problem’’ in the clinical
setting and thus determines the level and type of recommended
intervention.
The reasons that stimulants might be responsible for some
improvements in sleep remain theoretical. It is possible that use of
stimulants, at therapeutic levels that are sustained into the evening
hours,would reduceADHDsymptoms just before and at bedtime. By
Table 5. Changes in Sleep Scores During the 11-Week
Open-Label Dose-Optimization Phase (Study 2)
n
Mean (SD)
decreasea pb
CSHQ-Parent
Total 122 3.5 (6.44) <0.001
Bedtime Resistance 128 0.5 (1.72) 0.0013
Sleep Onset Delay 136 0.1 (0.89) 0.1037
Sleep Duration 132 0.4 (1.64) 0.0141
Sleep Anxiety 129 0.2 (1.34) 0.1698
Night Wakings 129 0.2 (1.16) 0.0296
Parasomnias 126 0.7 (1.75) <0.0001
Sleep-Disordered Breathing 129 0.1 (0.56) 0.0858
Daytime Sleepiness 132 1.5 (3.42) <0.0001
SSR
Total 129 2.2 (6.18) <0.0001
Bedtime 134 1.0 (4.02) 0.0056
Sleep Behavior 134 0.8 (2.60) 0.0008
Daytime Sleepiness 133 0.6 (1.74) 0.0001
ASHQ-Parent
Total 69 6.5 (12.26) <0.0001
Bedtime 69 1.2 (4.40) 0.0240
Sleep Behavior 69 1.4 (3.50) 0.0016
Waking During the Night 69 0.4 (2.46) 0.1398
Morning Waking 69 1.7 (3.59) 0.0002
Sleep Habits 69 0.3 (1.79) 0.1471
Daytime Sleepiness 69 1.0 (4.67) 0.0805
ASHQ-Self
Total 67 5.2 (11.53) 0.0004
Bedtime 67 0.9 (4.05) 0.0731
Sleep Behavior 67 1.1 (3.23) 0.0081
Waking During the Night 67 0.9 (2.45) 0.0033
Morning Waking 67 1.4 (3.81) 0.0031
Sleep Habits 67 -0.2 (2.42) 0.5668
Daytime Sleepiness 67 1.0 (4.05) 0.0505
aDecrease from beginning of the study to end of the OL phase or early
termination in the OL phase.
bFrom paired t-test.
ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ; Children’s
Sleep Habits Questionnaire; OL, open label; SD, standard deviation; SSR,
Sleep Self-Report.
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mitigating these symptoms, bedtime resistance might be attenuated,
facilitating an easier transition to sleep and initiation of sleep itself.
This study has limitations that should be considered in the
interpretation of results, some of which relate to measurement
issues. Sleep assessment was not the primary objective of either
Study 1 or Study 2, and these data are based on patient or paren-
tal report; thus, these findings may warrant further investigation
with objective measures of sleep such as actigraphy or poly-
somnography. Studies have generally not demonstrated a correla-
tion between subjective and objective assessments of sleep in
children with ADHD (Corkum et al. 2001; Wiggs et al. 2005;
Markovich et al. 2014), and it is likely that these various tools
measure somewhat different sleep constructs.
Our main goal in this analysis was to assess the impact of MPH-
MLR on clinically relevant practical sleep parameters, so we uti-
lized parent- and self-reports as being most legitimately reflective
of real-world parent and patient concerns. All the sleep measures
were, however, consistently used at all time points in the studies
and the results suggest considerable agreement between scales. In
addition, the ASHQ-Parent and ASHQ-Self report used in these
studies has not been fully validated; furthermore, children aged £12
years were included in this group and the CSHQ has only been
validated in children aged £10 years.
It also should be noted that sleep was assessed by both the parent
and the child/adolescent in the studies, and while the improvements
in the total score were directionally similar, they were numerically
larger when assessed by the parent. There was a discrepancy
between some parent- and self-report scores; for example, in Study
1, parents noted a worsening on the Daytime Sleepiness subscale,
while children reported an improvement. Similarly, adolescents in
Study 2 reported a worsening on the Sleep Habits subscale, while
parents reported an improvement. This underscores the importance
of querying both children/adolescents and caregivers about sleep.
The DB phase was brief in both studies (active drug was
administered for only 1 week). The forced dose randomization to
five groups in Study 2, with children systematically over- and
undermedicated, is not optimal for looking at drug versus placebo
effects on insomnia. Finally, the OL design precludes ruling out
unspecific factors such as rater bias and time effects. The argument
might be made, for example, that response fatigue (i.e., caregivers
being less likely to report problems as time goes on) may have been
at least partially responsible for the apparent decrease in sleep
symptoms observed during the OL phases. Not all sleep subscale
scores declined over time, however, and interestingly, the Sleep-
Disordered Breathing subscale, which would not be expected to be
impacted by stimulant therapy, did not change significantly during
the OL phase in either Study 1 or Study 2.
Children and adolescents with ADHD and sleep difficulties may
benefit from receipt of information about healthy sleep practices
(Weiss et al. 2006) as evidenced by two empirical trials (Hiscock
et al. 2015; Corkum et al. 2016).
Conclusions
Overall, the results of these studies replicate previous findings
suggesting that extended-release methylphenidate may be associ-
ated with short-term subjective reports of sleep onset delay in
children and adolescents compared with placebo, but that these
effects do not persist or worsen, and there may, in fact, be some
improvements in sleep parameters over time, as evidenced by lower
total and specific subscale scores during the OL phase on the CSHQ
and ASHQ. The findings suggest that adverse sleep effects of
stimulants, at least for some children with ADHD, may be transient
in nature, and that improvement in ADHD daytime symptoms
associated with stimulant administration may have a beneficial
impact on sleep. Future studies should address these and other
possible mechanisms for the differential effects of stimulants on
sleep and sleep behavior in children with ADHD.
Clinical Significance
Overall, the results of this analysis of two studies replicate pre-
vious findings that suggest that extended-release methylphenidate
may be associated with short-term subjective reports of sleep onset
delay comparedwith placebo; however, the findings also suggest that
these effects do not persist or worsen, and there may, in fact, be some
improvements in sleep parameters over time. One potential mecha-
nism for improvement in sleep parameters is that reduction inADHD
symptoms in the evening just before and at bedtime could reduce
bedtime resistance and facilitate settling and sleep onset.
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